Uptrend Call Working As AtriCure Stock Rises 21.0% (ATRC)
Comtex SmarTrend(R) - Thu Dec 18, 9:20AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 2 months, AtriCure has returned 21.03% as of today's recent price of $18.85.
ATRC: 18.76 (+0.13)
Volcano Acquired by Royal Philips for $1.2B: What Wall Street's Saying
at The Street - Wed Dec 17, 2:20PM CST
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
BSX: 13.13 (+0.07), SPNC: 34.50 (+0.59), ABT: 45.70 (-0.02), PHG: 29.39 (-0.06), MDT: 74.08 (+0.31), TRIV: 13.47 (-0.40), VOLC: 17.95 (+0.02), STJ: 66.67 (+0.67), THOR: 32.81 (+0.74), HTWR: 72.62 (+0.02), ELGX: 15.35 (-0.06), ATRC: 18.76 (+0.13), NVDQ: 16.90 (+0.55)
24.2% Return Seen to Date on SmarTrend AtriCure Call (ATRC)
Comtex SmarTrend(R) - Wed Dec 10, 9:15AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 2 months, AtriCure has returned 24.17% as of today's recent price of $19.34.
ATRC: 18.76 (+0.13)
AtriCure Has Returned 19.7% Since SmarTrend Recommendation (ATRC)
Comtex SmarTrend(R) - Tue Dec 02, 4:55PM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 2 months, AtriCure has returned 19.68% as of today's recent price of $18.64.
ATRC: 18.76 (+0.13)
Uptrend Call Working As AtriCure Stock Rises 18.2% (ATRC)
Comtex SmarTrend(R) - Tue Nov 25, 11:05AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 1 month, AtriCure has returned 18.20% as of today's recent price of $18.41.
ATRC: 18.76 (+0.13)
AtriCure Up 10.9% Since SmarTrend Uptrend Call (ATRC)
Comtex SmarTrend(R) - Mon Nov 03, 11:19AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 3 weeks, AtriCure has returned 10.88% as of today's recent price of $17.27.
ATRC: 18.76 (+0.13)
AtriCure Receives FDA Approval For Pivotal Study to Enroll Non-Paroxysmal Afib Patients
Business Wire - Mon Nov 03, 11:10AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced it has received approval for an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to begin enrollment in the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial. The DEEP trial is a prospective, multicenter, single arm, pivotal study to evaluate patients with persistent or long-standing persistent atrial fibrillation. This is the first pivotal study of its kind in the United States.
ATRC: 18.76 (+0.13)
Strength Seen in AtriCure (ATRC): Stock Gains 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:25AM CST
AtriCure (ATRC) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), GWPH: 68.08 (+1.82), ATRC: 18.76 (+0.13)
AtriCure Announces Upcoming Investor Conference Schedule
Business Wire - Fri Oct 31, 3:02PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Stifel Healthcare Conference 2014 at the Palace Hotel in New York City on Tuesday, November 18, 2014. Management is scheduled to present at 3:35 p.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation on the Investors page of AtriCure's corporate website at www.atricure.com.
ATRC: 18.76 (+0.13)
AtriCure's (ATRC) CEO Mike Carrel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 9:48PM CDT
ATRC: 18.76 (+0.13)
AtriCure beats by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 4:29PM CDT
ATRC: 18.76 (+0.13)
AtriCure (ATRC) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 3:25PM CDT
ATRC: 18.76 (+0.13)
AtriCure Reports Third Quarter 2014 Financial Results and Updates 2014 Outlook
Business Wire - Thu Oct 30, 3:02PM CDT
--U.S. sales of $20.1 million - up 26.7%
ATRC: 18.76 (+0.13)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:35PM CDT
ELLI: 41.40 (+0.81), AIV: 37.80 (-0.33), EPAY: 25.23 (-0.04), CPSI: 61.11 (-0.09), LNKD: 231.83 (+0.34), ADNC: 4.15 (+0.01), CODE: 34.55 (+0.64), HME: 66.47 (-0.43), ESIO: 7.76 (+0.13), HIL: 3.69 (-0.05), DGI: 30.85 (+0.27), AHT: 10.87 (-0.04), COLM: 44.76 (-0.62), AHS: 19.89 (+0.14), CSLT: 12.14 (+0.30), FRT: 136.26 (-0.13), DGII: 9.15 (+0.15), ADUS: 23.80 (-0.19), ESS: 210.72 (-1.86), EXPE: 89.01 (+0.09), IMPV: 51.87 (+1.18), CCI: 79.05 (-0.13), CPT: 75.44 (-0.56), GB: 49.34 (-0.36), AEGR: 21.59 (-0.27), ATEN: 4.29 (+0.01), ELGX: 15.35 (-0.06), AFFX: 9.80 (+0.05), CHE: 106.16 (+0.13), BCOV: 7.88 (-0.05), DCT: 35.96 (+0.21), ELX: 5.75 (+0.03), GNMK: 13.67 (+0.06), AXTI: 2.65 (-0.09), INT: 47.79 (-0.05), EGN: 64.33 (-0.02), EGO: 5.97 (+0.18), GMED: 24.37 (+0.44), GDOT: 20.42 (+0.25), KEG: 1.73 (+0.01), ISBC: 11.14 (+0.04), GRPN: 7.89 (-0.14), ALJ: 12.54 (+0.04), CTRL: 14.57 (-0.04), GPRO: 66.41 (+4.87), EMN: 76.80 (+0.04), IMMR: 9.45 (+0.47), CUBE: 22.59 (+0.08), BYI: 83.27 (unch), ATRC: 18.76 (+0.13), BYD: 12.28 (+0.14), FLDM: 32.31 (+0.30), BEAT: 10.15 (+0.09), FLR: 60.30 (-0.26), FLT: 149.17 (-0.93), EHTH: 27.13 (+0.97)
AtriCure Completes Enrollment in Post Approval Study for the Synergy(TM) Ablation System
Business Wire - Thu Oct 09, 3:02PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced enrollment in the ABLATE Post Approval Study (PAS) is complete.
ATRC: 18.76 (+0.13)
Shares of ATRC Down 15.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 09, 10:01AM CDT
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on July 9th, 2014 at $16.50. In approximately 3 months, AtriCure has returned 15.31% as of today's recent price of $13.97.
ATRC: 18.76 (+0.13)
AtriCure to Announce Third Quarter 2014 Financial Results
GlobeNewswire - Fri Oct 03, 3:02PM CDT
AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, will release its financial results for the third quarter of 2014 on Thursday, October 30, 2014.
ATRC: 18.76 (+0.13)